Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bajaj Healthcare Limited Secures SEC-CDSCO Nod for Phase III Trials of Cenobamate
Details : Bajaj is working on a generic version of the anti-seizure medication, cenobamate, as part of its efforts to expand its portfolio in the epilepsy treatment market.
Product Name : Cenobamate-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 20, 2025
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Posaconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bajaj Healthcare Launches Posaconazole API for Treatment of Black Fungus Infection
Details : Posaconazole is a triazole antifungal agent indicated for treating Mucormycosis patients popularly known as Black Fungus in post Covid complications.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2021
Lead Product(s) : Posaconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
